drugset / Trial / NCT06700096
An Open-Label, Comparative Study of the Efficacy, Safety and Pharmacodynamics of Single Dose of ANB-002 in Patients With Hemophilia B
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The aim of the study is to demonstrate non-inferiority of ANB-002 compared with preventive use of coagulation factor IX (FIX) in adult subjects with hemophilia B with FIX activity ≤2% and without FIX inhibitor. The study will have an open-label single-arm design.
Timeline
- Start
- 2024-11-07
- Primary completion
- 2027-04
- Completion
- 2032-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | arvenacogene sanparvovec | Gene therapy (AAV / viral vector) | — | — |